List of Excipients in Branded Drug MOVIPREP

« Back to Dashboard

MOVIPREP Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 29, 2026

MOVIPREP is a polyethylene glycol 3350 bowel-preparation product differentiated by a two-sachet formulation, electrolyte replacement, ascorbate-driven osmotic activity, lemon flavor, and a reduced-volume dosing regimen. The strongest commercial opportunities are improved taste, lower patient burden, ready-to-drink delivery, private-label supply, regional reformulation, and generic or hybrid regulatory pathways. Excipient changes must preserve osmotic performance, electrolyte balance, stability, microbial control, and patient tolerability.

What is MOVIPREP and how does its formulation work?

MOVIPREP is an oral bowel-cleansing product containing macrogol, also known as polyethylene glycol 3350, with sodium sulfate, sodium chloride, potassium chloride, ascorbic acid, and sodium ascorbate. The product is supplied as separate Sachet A and Sachet B powders that are dissolved in water before administration.

The U.S. formulation provides the following quantities per approximately 1 liter of reconstituted solution:

Component	Approximate quantity	Primary function
Polyethylene glycol 3350	100 g	Nonabsorbed osmotic agent; retains water in the gastrointestinal tract
Sodium sulfate	7.5 g	Electrolyte and osmotic contribution
Sodium chloride	2.691 g	Sodium and chloride replacement
Potassium chloride	1.015 g	Potassium replacement
Ascorbic acid	4.7 g	Additional osmotic load and acidulant
Sodium ascorbate	5.9 g	Ascorbate source and buffering contribution
Flavoring	Product-specific	Taste masking
Sweetener	Product-specific	Taste improvement

The formulation combines PEG-induced water retention with ascorbate and sulfate osmotic effects. The electrolytes are included to reduce net electrolyte shifts during high-volume diarrhea and rapid intestinal transit. MOVIPREP is not interchangeable with a simple PEG-only powder unless the new formulation demonstrates comparable bowel cleansing and an acceptable electrolyte and safety profile.[1]

What excipients are used in MOVIPREP?

MOVIPREP has a relatively limited excipient platform. The commercial value lies less in the number of excipients than in their interaction with a high-load, acidic, salty solution.

Flavoring and sweeteners

The reconstituted product has a strong mineral, acidic, and citrus profile. Flavoring and sweetener selection is therefore a central formulation variable. Product labeling differs by market, and the exact flavor system may include lemon or citrus flavoring and high-intensity sweeteners such as sucralose or acesulfame potassium, depending on the jurisdiction and presentation.[1,2]

Potential excipient strategies include:

• Citrus systems with lower bitterness and lower lingering acidity.
• Flavor combinations designed to mask sulfate and ascorbate notes.
• Sweetener blends using sucralose, acesulfame potassium, steviol glycosides, or other approved high-intensity sweeteners.
• Flavor systems compatible with pediatric or geriatric use.
• Separate flavor options supplied in a multi-variant commercial pack.
• Natural flavor systems for markets that restrict artificial flavor claims.

The principal technical risk is that a flavor or sweetener may alter chemical stability, increase precipitation, create haze, or produce an unacceptable taste after dilution into one or two liters of water.

Acids, buffers, and pH modifiers

Ascorbic acid and sodium ascorbate create an acidic ascorbate system. Any change to the acid-base profile can affect:

• Taste intensity.
• PEG stability.
• Mineral solubility.
• Color formation.
• Container compatibility.
• Microbial stability after reconstitution.
• Patient tolerability.

Adding conventional buffers may improve palatability but could reduce product differentiation or alter the electrolyte burden. A buffer strategy is commercially attractive only if it improves taste without changing the pharmacodynamic osmotic profile.

Anti-caking and powder-flow excipients

The product is a high-dose powder blend containing hygroscopic salts and acidic components. Suitable anti-caking and flow aids can improve:

• Sachet filling accuracy.
• Blend uniformity.
• Powder transfer from the sachet.
• Resistance to humidity.
• Manufacturing throughput.

Candidate excipients include colloidal silicon dioxide and other permitted flow aids. Their use is constrained by the need to maintain rapid dissolution and avoid visible particles in the reconstituted solution.

Sachet and packaging materials

Packaging is a functional part of the excipient strategy. Sachet materials must protect the blend from moisture and limit oxygen exposure where ascorbate degradation is a concern.

Commercially relevant options include:

• High-barrier foil laminate sachets.
• Multi-layer polymer films with moisture protection.
• Unit-dose blister or stick-pack formats.
• Recyclable high-barrier structures.
• Separate packaging for Sachet A and Sachet B to prevent chemical interaction during storage.

Packaging changes can create a regulatory variation even when the formulation remains unchanged. Moisture uptake, assay drift, impurity growth, powder caking, and dissolution time are critical stability endpoints.[3]

What formulation characteristics protect MOVIPREP commercially?

The commercial formulation is protected primarily by the combination of composition, dosing sequence, electrolyte content, and patient-use instructions rather than by a single excipient.

Important formulation attributes include:

1. Two-sachet segregation before use.
2. High PEG 3350 loading.
3. Ascorbic acid and sodium ascorbate as supplemental osmotic agents.
4. Defined sodium, potassium, chloride, and sulfate content.
5. Powder format with extemporaneous dilution.
6. Lemon or citrus taste system.
7. Split-dose administration.
8. A reduced-volume regimen compared with traditional 4-liter PEG solutions.

A competitor can avoid literal duplication by changing flavor, sweetener, sachet configuration, concentration, or dosing volume. It still must establish equivalent cleansing performance and manage the risk that a formulation difference changes safety, tolerability, or regulatory classification.

What commercial excipient opportunities exist for MOVIPREP?

1. Taste-masked MOVIPREP alternatives

Taste is the most direct excipient opportunity. Patients commonly experience salty, acidic, bitter, or medicinal notes with bowel preparations. A product with improved taste could compete without changing the active osmotic architecture.

Potential product concepts include:

• Lemon-lime or grapefruit flavor.
• Mild orange or berry-citrus flavor.
• Lower-acidity flavor systems.
• Dual-flavor packs.
• Separate flavor sachets added immediately before dosing.
• Sweetener systems optimized for lower aftertaste.

A separate flavor sachet creates a relatively low-risk commercial variant, but it may not provide strong patent protection unless the flavor system has measurable performance advantages.

2. Lower-volume and concentrated formats

The existing product requires substantial fluid intake. A concentrated formulation that reduces the volume of prepared solution could improve adherence, but it would increase the risk of hyperosmolarity, nausea, vomiting, electrolyte disturbance, and renal complications.

This opportunity requires more than an excipient substitution. It may require:

• New dose-ranging studies.
• Comparative cleansing trials.
• Electrolyte and renal safety monitoring.
• Revised administration instructions.
• New container-closure and stability studies.

A lower-volume product could command a premium if it materially improves completion rates.

3. Ready-to-drink or liquid-filled presentations

Ready-to-drink products eliminate powder dissolution and reduce preparation errors. They also create higher manufacturing, shipping, and packaging costs.

The principal technical barriers are:

• Long-term stability of ascorbate.
• Color and flavor drift.
• Microbial control.
• Container compatibility.
• Oxygen ingress.
• Higher transportation weight.
• Potential need for preservatives or aseptic processing.

A ready-to-drink presentation would likely require a new drug application supplement or an equivalent regulatory pathway, depending on the degree of formulation and manufacturing change.

4. Pediatric and geriatric presentations

Pediatric and geriatric patients may have greater difficulty tolerating large volumes and strong flavors. Opportunities include:

• Lower per-dose sachets.
• Age-specific flavor profiles.
• Easier-open packaging.
• Premeasured water containers.
• Dosing aids.
• Clear instructions for split dosing.

Pediatric use requires particular attention to electrolyte exposure, fluid balance, and the evidence base supporting bowel cleansing in the intended age range.

5. Sugar-free, allergen-conscious, and diet-compatible variants

A sugar-free product is commercially aligned with existing bowel-prep positioning because high-intensity sweeteners are already commonly used. Additional opportunities include:

• Gluten-free claims where applicable.
• Lactose-free claims.
• Vegan-compatible excipient systems.
• Halal or kosher certification.
• Avoidance of specific dyes or artificial colors.
• Reduced sodium variants, subject to clinical and regulatory support.

These claims can support pharmacy substitution resistance and institutional procurement, but they provide limited exclusivity unless combined with a technically distinctive formulation.

What is the FDA regulatory status of MOVIPREP?

MOVIPREP was approved in the United States under NDA 021881 in 2006. The product is regulated as a prescription bowel-preparation drug and is listed in FDA drug-labeling and Orange Book systems under its approved product information.[1,4]

The original five-year new chemical entity exclusivity period would have ended in 2011. MOVIPREP is therefore a mature product from an U.S. regulatory-exclusivity perspective. Its commercial protection depends on any surviving formulation, method-of-use, manufacturing, or packaging rights, together with brand recognition, supply reliability, physician familiarity, and payer or pharmacy channel execution.

MOVIPREP is a small-molecule drug product. Biosimilar rules do not apply. Competition would arise through generic, abbreviated, hybrid, or locally authorized equivalent products rather than through biosimilar applications.

When does MOVIPREP lose exclusivity?

MOVIPREP has already lost its original U.S. new chemical entity exclusivity. The relevant commercial question is whether any enforceable patents or listed patents remain in the target jurisdiction.

Patent risk should be assessed across four categories:

Patent category	Relevance to MOVIPREP	Typical competitive impact
Core composition	PEG-electrolyte-ascorbate combination	Usually limited for a mature product unless claims remain enforceable
Formulation	Flavor, sweetener, concentration, stability, or dissolution	Can delay or complicate direct copying
Method of use	Split dosing, cleansing regimen, or patient population	May create labeling and litigation risk
Manufacturing and packaging	Blend segregation, moisture control, sachet technology	More relevant to supply-chain replication than basic generic entry

A generic applicant may pursue a Paragraph IV certification against listed patents. A Paragraph IV notice can trigger patent litigation and, if suit is filed within the statutory period, an automatic stay of approval for up to 30 months under the Hatch-Waxman framework.[5]

The commercial impact depends on whether the challenged patent claims cover the approved product, whether the claims are valid and infringed, and whether the generic applicant can use a carve-out label for patented methods of use.

How many patents cover MOVIPREP?

The number of relevant patents cannot be reduced to a single global figure because patent coverage differs by country, product version, assignee, continuation history, and Orange Book listing status.

For commercial diligence, the relevant count should distinguish:

• U.S. patents listed for NDA 021881.
• Expired U.S. patents.
• Pending continuation or reissue applications.
• European and national-phase patents.
• Formulation patents covering specific excipient combinations.
• Method-of-use patents covering bowel cleansing or split dosing.
• Manufacturing patents covering separate sachet preparation.
• Packaging patents covering moisture-resistant unit-dose systems.

Older PEG bowel-preparation patents generally face substantial age and obviousness pressure because PEG-electrolyte solutions, flavoring, sweetening, and unit-dose packaging are established technologies. A new entrant’s strongest patent strategy is more likely to focus on a measurable technical improvement, such as reduced volume, improved taste, enhanced stability, or a novel delivery format.

Which companies are challenging or competing with MOVIPREP?

MOVIPREP competes in a crowded bowel-preparation market rather than in a single-product category.

Product or category	Key formulation approach	Commercial relevance
GoLYTELY and generic PEG-electrolyte solutions	Large-volume PEG and electrolyte solution	Lower-cost benchmark; high fluid burden
MiraLAX-based regimens	PEG 3350 without the same proprietary electrolyte architecture	Widely used but may involve off-label or protocol-dependent use
SUPREP	Sodium sulfate, potassium sulfate, and magnesium sulfate	Low-volume sulfate-based competitor
PLENVU	High-concentration PEG and electrolyte/ascorbate system	Direct low-volume competitive benchmark
Sutab	Sulfate-based tablets	Avoids liquid taste but requires many tablets and water
Clenpiq and similar liquid products	Ready-to-drink or lower-preparation-burden approach	Convenience-focused competition

The strongest direct comparison is with PLENVU because both products use PEG, electrolytes, and ascorbate-related osmotic activity. SUPREP and Sutab compete on lower liquid burden, while GoLYTELY competes on established use and lower cost.

How does MOVIPREP compare with PLENVU and SUPREP?

Attribute	MOVIPREP	PLENVU	SUPREP
Primary osmotic platform	PEG 3350, sulfate, ascorbate	PEG and electrolyte/ascorbate system	Sulfate salts
Physical presentation	Powder sachets	Powder sachets	Liquid concentrate
Main differentiator	Established split-dose PEG formulation	Lower-volume formulation	Low-volume sulfate regimen
Excipient opportunity	Taste, packaging, flavor, dissolution	Taste and concentration	Flavor, tolerability, container design
Main patient burden	Taste and fluid intake	Taste and fluid intake	Strong taste and fluid intake
Main regulatory risk for reformulation	Electrolyte and osmolality changes	Concentration and safety changes	Sulfate exposure and renal/electrolyte issues

MOVIPREP has a defensible commercial position where prescribers prefer a PEG-based preparation and patients can tolerate the required fluid intake. PLENVU has greater differentiation through lower volume. SUPREP competes through a different salt platform and a concentrated liquid format.

What generic launch risks exist for MOVIPREP?

Generic entry risks are moderate rather than high for the active ingredients, but they can be meaningful for a direct formulation copy.

The principal risks are:

• Orange Book patent litigation.
• Difficulty reproducing flavor acceptance.
• Dissolution and powder-flow variability.
• Sachet-to-sachet content uniformity.
• Stability loss from moisture ingress.
• Electrolyte deviations.
• Labeling limitations from method-of-use patents.
• Hospital and pharmacy substitution requirements.
• Temporary supply disruption during manufacturing scale-up.
• Liability exposure from renal or electrolyte adverse events.

A generic applicant can reduce risk by using a different flavor system, different sweetener, or different sachet architecture. That approach may avoid some formulation claims but requires careful comparative quality and clinical assessment.

What manufacturing and intellectual-property barriers affect MOVIPREP?

Manufacturing barriers are practical and can be more important than basic active-ingredient access. The product requires accurate blending of high-dose PEG with lower-dose potassium chloride and other salts. Segregation during transfer or filling can produce content-uniformity failures.

Critical manufacturing controls include:

• Particle-size matching.
• Blend-time control.
• Humidity management.
• Potassium chloride distribution.
• Sachet fill-weight accuracy.
• Separation of incompatible components.
• Moisture-barrier packaging.
• Reconstitution-time testing.
• Stability monitoring for ascorbate degradation.

A new manufacturer may need separate blending and filling campaigns for Sachet A and Sachet B. These requirements raise cost but also create opportunities for contract manufacturers with high-potency powder handling, pharmaceutical sachet equipment, and validated moisture-control systems.

What licensing and commercial partnership opportunities exist?

MOVIPREP-related licensing opportunities are more likely to arise from regional commercialization and manufacturing rights than from new-molecule licensing.

Potential deal structures include:

• Territory-specific distribution licenses.
• Private-label supply agreements.
• Co-development of alternate flavors.
• Contract manufacturing of Sachet A and Sachet B.
• Hospital or pharmacy-chain supply contracts.
• Licensing of ready-to-drink or concentrated presentations.
• Acquisition of regional marketing authorizations.
• Bundled colorectal-screening programs with diagnostic providers.

The most attractive partner assets are regulatory approvals, local reimbursement access, established endoscopy-center relationships, and validated sachet manufacturing capacity.

What is the revenue exposure from MOVIPREP competition?

Revenue exposure depends on brand share, the number of authorized generic suppliers, payer substitution, and the availability of lower-volume alternatives. The main pricing pressure comes from generic PEG-electrolyte products and institutional procurement contracts. Premium pricing is more sustainable for products that reduce preparation volume, improve taste, or simplify administration.

A commercial model should separate:

1. Branded MOVIPREP revenue.
2. Generic-equivalent revenue.
3. Regional licensing revenue.
4. Private-label manufacturing revenue.
5. Premium reformulation revenue.
6. Contracted hospital and endoscopy-center volume.

A flavor-only reformulation may support modest differentiation but is unlikely to sustain a large premium without clinical evidence. A lower-volume or ready-to-drink product has greater revenue potential but also carries substantially higher development and manufacturing costs.

How strong is the MOVIPREP patent estate?

The legacy estate is likely stronger as a regulatory and commercial platform than as a broad, long-duration composition patent position. The core ingredients are established, and the original approval dates place MOVIPREP in a mature exclusivity phase.

Patent strength is highest where claims cover:

• A specific concentration range.
• A defined ascorbate-to-PEG relationship.
• A demonstrated reduction in fluid burden.
• A particular stability advantage.
• A novel flavor or sweetener combination with objective performance data.
• A specialized sachet or moisture-barrier system.
• A clinically supported dosing method.

Patent strength is weaker where claims merely recite routine PEG, electrolyte, flavoring, sweetening, or packaging components without a demonstrated technical effect.

Key Takeaways

• MOVIPREP uses PEG 3350, sulfate, chloride, potassium, ascorbic acid, and sodium ascorbate in a two-sachet powder system.
• Flavor, sweetener, pH, moisture control, and sachet architecture are the main excipient levers.
• The strongest commercial opportunities are taste improvement, lower-volume delivery, ready-to-drink formats, pediatric or geriatric presentations, and private-label supply.
• MOVIPREP’s U.S. new chemical entity exclusivity ended years ago; current entry risk depends on surviving patents and regulatory requirements.
• Biosimilar competition does not apply because MOVIPREP is a small-molecule drug product.
• A direct generic can compete on cost, but a differentiated product can compete on taste, volume, convenience, and adherence.
• Patent claims based only on routine excipient substitutions are vulnerable; claims supported by measurable stability, palatability, or cleansing advantages are stronger.
• Manufacturing capability in moisture-controlled powder blending and dual-sachet filling is a meaningful barrier to entry.

FAQs

Can MOVIPREP be reformulated with a different sweetener?

Yes, but the reformulation must address taste, stability, dissolution, impurity formation, and regulatory comparability. A sweetener change alone is unlikely to create strong exclusivity without supporting technical data.

Is a ready-to-drink MOVIPREP product commercially attractive?

Yes. It could reduce preparation errors and improve convenience, but liquid stability, ascorbate degradation, microbial control, shipping cost, and container compatibility create major development barriers.

Can a generic company omit a patented MOVIPREP method of use?

Potentially. A generic applicant may use a section viii labeling carve-out where legally and regulatorily permitted. The feasibility depends on the scope of the listed method-of-use claim and the required dosing instructions.

Which excipient change offers the fastest commercial path?

A flavor, sweetener, packaging, or dosing-instruction variant generally offers a faster path than a concentrated or ready-to-drink reformulation. The required regulatory pathway depends on the jurisdiction and the magnitude of the change.

Does MOVIPREP have biosimilar risk?

No. MOVIPREP contains small-molecule active ingredients and competes through generic, hybrid, or reformulated drug products rather than biosimilar applications.

References

1. U.S. Food and Drug Administration. (2023). MOVIPREP (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, ascorbic acid, and sodium ascorbate) prescribing information.
2. National Library of Medicine. (2024). DailyMed: MOVIPREP- polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, ascorbic acid, and sodium ascorbate powder, for solution.
3. International Council for Harmonisation. (2003). ICH Q1A(R2): Stability testing of new drug substances and products.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2017). M9? Hatch-Waxman and patent certification guidance for industry.